newwin
Luciann Nguyen
Settings
← Accounts
biotech

Suzhou Abogen Biosciences Co., Ltd.

42
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Suzhou Abogen Biosciences Co., Ltd.

New trial — Study of ABO2102 in KRAS-Mutated Solid Tumors

New trialNCT07455617
42/100
Opportunity
Commercial fit5/25
Clinical timing20/20
Biomarker need0/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT07455617 posted by Suzhou Abogen Biosciences Co., Ltd.: "Study of ABO2102 in KRAS-Mutated Solid Tumors". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 155 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT07455617
Study of ABO2102 in KRAS-Mutated Solid Tumors
phase 1
—